Navigation Links
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
Date:5/29/2009

COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) breast cancer, and a separate study investigating neratinib safety and efficacy when given with paclitaxel (Taxol(R), Bristol-Myers Squibb) in patients with HER-2 dependent solid tumors. The data gathered from both trials are scheduled to be presented at the 45th Annual Meeting of the American Society of Clinical Oncology Annual Meeting in Orlando, Florida, from May 29 to June 2, 2009. Neratinib is an investigational orally administered irreversible inhibitor of the HER-2 and EGFR kinases.

"The data gathered from these studies provide additional evidence suggesting that neratinib, when combined with these therapies, is an active agent in HER-2 positive breast cancer," says Ramona Swaby, M.D., Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA. "While improvements have been made in treating HER-2 positive breast cancer, there remains an unmet medical need for more therapies for patients with metastatic breast cancer. These data warrant ongoing and future investigations to further understand and evaluate the utility of neratinib against this aggressive disease."

Neratinib (HKI-272) in Combination with Trastuzumab for the Treatment of Advanced Breast Cancer

This ongoing phase 1/2 study of neratinib in combination with trastuzumab evaluated patients with advanced ErbB-2 positive breast cancer that progressed following therapy with trastuzumab, the standard of care in this disease setting. The primary endpoint of the two-part study is 16-week progression-free survival (PFS). The first part of
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
2. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
3. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
4. Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
5. Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
6. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
7. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
8. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
9. Preliminary Data From Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa
10. What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study
11. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty ... for the second quarter ended June 30, 2014. ... $6.5 million in the second quarter of 2014, an increase ... Total revenues of $13.3 million for the six months ended ... period in 2013 , Total revenues generated from the ...
(Date:7/24/2014)... ATLANTA , July 24, 2014  Alimera Sciences, ... company that specializes in the research, development and commercialization ... release its second quarter of fiscal year 2014 financial ... 2014. An investor conference call will follow on the ... The conference call will be hosted by Dan ...
(Date:7/24/2014)... BUFFALO, N.Y. , July 24, 2014  Kinex ... US FDA for the Company,s KX2-391 Ointment for the ... keratosis. This is the Company,s third IND to be ... months. KX2-391 is a synthetic, orally active ... and tubulin polymerization. KX2-391 promotes the induction of p53, ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... Asthmatx, Inc. presented the results of a series ... thermoplasty delivered by the Alair® System, and how this ... in a poster at the 2009 Annual Meeting of ... in Miami Beach, Fla. , The poster, titled "Where ...
... PALO ALTO, Calif., Nov. 9 Women,s sexual health company, ... as it prepares for a 2010 launch of its Viveve ... a name that we believe captures the essence of our ... president and chief executive. "Viveve exists for the sole purpose ...
Cached Medicine Technology:Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting 2Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting 3Women's Sexual Health Company Changes Name in Preparation for Market Entry 2
(Date:7/25/2014)... (PRWEB) July 25, 2014 iTanSmart is ... and iPads. The app provides a tailored approach to ... potentially dangerous sunburns and skin damage. In his review, ... sounds, and capabilities of iTanSmart. , Eaton begins ... app as a ‘better organized’ and ‘great alternative’ to ...
(Date:7/25/2014)... According to the Liver Cirrhosis ... Vkool.com, this is a comprehensive guide that provides ... safe remedies for liver cirrhosis . This ...     Chapter 1: Liver Cirrhosis Bible & ... About Liver Basics ,     Chapter 3: Getting ...
(Date:7/25/2014)... July 25, 2014 At World T.E.A.M. ... July 19, 17 participating developmentally-disabled teens and young adults ... if off-road bicycling, canoeing and hiking can be challenging. ... at the scenic Chesapeake and Ohio Canal National ... athletes both disabled and able-bodied. Under slightly overcast skies ...
(Date:7/24/2014)... 2014 Dr. Henry H. Ting, a ... has been appointed senior vice president and chief quality ... his new role, he will oversee the hospital's clinical ... successfully led quality initiatives and interprofessional teams at the ... for the Door-to-Balloon Alliance, a collaboration of more than ...
(Date:7/24/2014)... bearing human breast tumors, exposure to dim light at ... drug tamoxifen, according to data published in Cancer ... Cancer Research. The negative effects of dim light exposure ... melatonin supplement during the night. , "Resistance to tamoxifen ... breast cancer," said Steven M. Hill, PhD, professor of ...
Breaking Medicine News(10 mins):Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 2Health News:Liver Cirrhosis Bible & Ezra Protocol Review Exposes Debra Elkin's Liver Cirrhosis Treatment Guide – Vkool - Better Information, Better Lives 3Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 2Health News:NewYork-Presbyterian Hospital Names New Senior Vice President for Quality and Patient Safety 3Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Nov. ... known as "K2" is sending young people to the ... toxicologists warn. In recent months, physicians and toxicologists ... emergency rooms after smoking synthetic marijuana. Despite the side ...
... calculations in the supercomputer MareNostrum at the Barcelona Supercomputing ... for Research in Biomedicine (IRB Barcelona) have presented the ... this new database holds more than 1,700 proteins and ... has been developed to study the basic biology of ...
... Nov. 11 (HealthDay News) -- Long-term use of vitamin E ... in men, a new study finds. "An estimated 20.5 ... some evidence of age-related cataract," wrote study author William G. ... in Boston, and colleagues, in a news release. Because ...
... , THURSDAY, Nov. 11 (HealthDay News) -- Many U.S. ... dinner, meals that provide nutrients critical to youngsters, development, ... The American Dietetic Association Foundation poll of 1,193 ... found that breakfast is sometimes missed by 42 percent ...
... American Society of Nephrology (ASN) proudly highlight the ... The Halpin Foundation-ASN Research Grant, created to help ... provides recipients transition funding toward successful application for ... (McGill University Faculty of Medicine), the 2008 recipient ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... depicting emaciated lung cancer patients, a dead body in a ... of secondhand smoke) and other consequences of smoking that will ... people into quitting the habit or not starting in the ...
Cached Medicine News:Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 2Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 3Health News:Scientists at IRB Barcelona and BSC publish the world's largest video data bank of proteins 2Health News:Study Finds Vitamins E and C Don't Reduce Cataract Risk in Men 2Health News:Many Kids Skipping Meals, Snacking Instead 2Health News:Putting the spotlight on membranous nephropathy 2Health News:FDA Proposes Graphic Warnings on Cigarette Packs 2Health News:FDA Proposes Graphic Warnings on Cigarette Packs 3
... is a basic laboratory system for pH ... can be obtained when used with a ... • Fast and easy one and two-point ... five buffers (pH 1.68, 4.00, 7.00, 10.01 ...
... Multimode Detectors provide unmatched value and ... and automation needs. Capable of performing ... the same instrument, the DTX Series ... can be integrated seamlessly with Beckman ...
... is a dual-monochromator, multi-detection microplate reader ... 6-384 microplate reading capability. Detection modalities ... intensity (FI) and have optical performance ... or spectrophotometer. Endpoint, kinetic, spectrum and ...
... microplate reader combines improved flexibility ... with a wide range of ... the flexibility, sensitivity and high ... is the ideal detection solution ...
Medicine Products: